Core Laboratories (CLB) EBITDA (2022 - 2026)

Core Laboratories' EBITDA history runs 5 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• On a quarterly basis, EBITDA fell 57.28% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $53.9 million, a 0.85% decrease from a year earlier, with the FY2025 full-year figure at $56.5 million, down 3.57% from the prior year.
• EBITDA eased to $1.9 million in Q1 2026 per CLB's latest filing, from $15.8 million in the prior quarter.
• Across five years, EBITDA topped out at $20.9 million in Q3 2025 and bottomed at $1.9 million in Q1 2026.
• The 5-year median for EBITDA is $14.7 million (2022), against an average of $13.3 million.
• Across the five-year window, EBITDA jumped 62.26% in 2023 and plunged 57.28% in 2026, its largest moves.
• Year by year, EBITDA stood at $15.6 million in 2022, then declined by 6.64% to $14.6 million in 2023, then dropped by 2.79% to $14.2 million in 2024, then rose by 11.7% to $15.8 million in 2025, then sank by 88.08% to $1.9 million in 2026.
• Per Business Quant, the three latest CLB EBITDA figures stand at $1.9 million (Q1 2026), $15.8 million (Q4 2025), and $20.9 million (Q3 2025).